Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Severe Nail Psoriasis and Early Psoriatic Arthritis: Illustrative Cases Confirming That Severity of Disease Is Not Solely Dependent on the Extent of Body Surface Area.","authors":"Graham H Litchman, Diego Ruiz Dasilva, James Q Del Rosso","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nail psoriasis is a chronic inflammatory manifestation frequently associated with cutaneous psoriasis and psoriatic arthritis (PsA). Fingernails and/or toenails may be affected by psoriasis. The management of nail psoriasis can be challenging due to marked variability in clinical presentation, its chronicity, its frequent refractory nature despite a variety of therapies, and the slow rate of nail plate growth over several months. Unfortunately, the common clinical misdiagnosis as onychomycosis often leads to delay in an accurate diagnosis of nail psoriasis as well as exposure of the patient to topical and/or oral antifungal therapies that are not effective for psoriasis. Traditional treatment options for nail psoriasis often require extended courses of therapy to achieve significant results. Both of these cases were characterized by limited or absent psoriatic skin involvement, with extensive symptomatic psoriatic fingernail dystrophy and presence of PsA. This article describes the use of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the rapid resolution of severe psoriasis in 2 patients with extensively dystrophic fingernail psoriasis and concomitant PsA, both causing marked interference with daily physical functioning and significant psychosocial impairment. Both patients rapidly achieved marked improvement of all signs and symptoms of severe psoriasis involving all affected fingernails and joints, within at least 1 to 3 months. These results add real-world evidence that further highlights the potential for accelerated improvement with specific biologic therapies effective for plaque psoriasis, with both cases supporting the rapid onset and high magnitude of efficacy for symptomatic severe psoriasis presenting with extensive dystrophy of all fingernails and PsA.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant Exosome Injection: A New Boost for Postlaser Vascular Repair.","authors":"Noury Adel, Youn Kyong Jo, Ida Vega Thulesen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Microvascular activation is a pivotal early event in oral wound healing, particularly in laser-induced injuries where thermal effects alter endothelial behavior. CD31, a key endothelial adhesion and signaling molecule, provides a reliable marker for evaluating angiogenic onset, vessel reorganization, and endothelial stability. Plant-derived nanovesicles (PDNVs) have emerged as promising biotherapeutics capable of modulating cellular communication, yet their influence on CD31-mediated vascular remodeling in laser wounds remains largely unexplored.</p><p><strong>Objective: </strong>To investigate how 2 distinct PDNV formulations modulate CD31 expression and CD31+ microvascular density in standardized blue diode laser wounds created in rabbit tongue tissue.</p><p><strong>Methods: </strong>Controlled 450-nm diode laser micro-incisions were produced on rabbit tongues and treated locally with either Exoline or Glow exosomes. Untreated wounds served as controls. Tissue samples were harvested at baseline, Day 3, and Day 7. Histological evaluation focused primarily on CD31 immunohistochemistry to quantify endothelial activation, vessel budding, and remodeling intensity. Additional morphologic assessments supported interpretation of vascular changes.</p><p><strong>Results: </strong>Both PDNV formulations significantly increased CD31+ endothelial structures compared to controls. Exoline induced the highest early CD31 expression, accompanied by dense microvascular sprouting and pronounced endothelial clustering by Day 3. Glow produced a moderate but consistent elevation in CD31 labeling, with more gradual vessel organization. By Day 7, Exoline-treated wounds exhibited mature, well-oriented vessel networks, whereas Glow-treated tissues showed intermediate remodeling.</p><p><strong>Conclusion: </strong>PDNVs effectively enhance CD31-mediated angiogenic activation following laser-induced mucosal injury, with Exoline demonstrating the most robust endothelial response. These findings highlight PDNVs as promising modulators of early microvascular remodeling in oral regenerative contexts.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"10-15"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs Surgeons' Postoperative Care Practices for Secondary Intention Healing: A National Survey.","authors":"Vixey Silva, Lisa Fronek, Travis Blalock, Emily Coughlin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This paper seeks to characterize Mohs surgeons' postoperative wound care practices for secondary intention healing (SIH) and identify trends in the use of topical agents and perceived clinical outcomes.</p><p><strong>Methods: </strong>A survey was distributed to American College of Mohs Surgery (ACMS) members to assess demographics, practice settings, wound care preferences, and self-reported outcomes related to SIH. Fisher's exact and χ² tests were used to evaluate associations between surgeon characteristics and wound care practices.</p><p><strong>Results: </strong>Petroleum emollients were used by 96.4% of respondents. Topical antibiotics, most commonly mupirocin and gentamicin, were routinely recommended by 36.1% and were associated with higher reported infection rates (<i>P</i>=0.034). Antiseptic solutions, particularly dilute acetic acid, were more often used by early-career surgeons (<i>P</i>=0.016). Only 10.8% of respondents used topical timolol. Conventional nonadherent dressings were preferred by 91.6% of respondents. Most surgeons reported complete healing within 4 to 8 weeks (72.3%), 95.2% of surgeons indicated infection rates of 5% or less, and 95.2% reported good to excellent cosmetic outcomes.</p><p><strong>Limitations: </strong>Low response rate and self-reported data limited generalizability. Wound location data were not stratified.</p><p><strong>Conclusion: </strong>Postoperative care practices for SIH vary considerably among Mohs surgeons. Despite supporting literature, the use of advanced dressings, antiseptics, and topical timolol remains limited. These findings highlight opportunities for further research and standardization of SIH wound care.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Trial Evaluating the Safety and Efficacy of a Serum Containing Plant Adaptogens in Patients With Mild-to-Moderate, Persistent Centrofacial Erythema Associated With Rosacea.","authors":"Zoe Diana Draelos, Jacqueline Watchmaker, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Persistent facial erythema is one of the most common subtypes of rosacea, often prompting patients to seek treatment. Characterized by multiple factors including adaptive immune and vascular dysregulation, genetics, and environmental influences, skincare measures aimed at reducing erythema and strengthening the skin barrier are fundamental to treatment. Plant adaptogens are rich phytochemicals that promote homeostasis, helping to increase resistance to stress, mitigate inflammation, support the skin barrier, and prevent premature aging. A serum containing plant adaptogens demonstrated significant improvements from baseline in global skin quality in subjects with mild-to-severe facial photodamage over 12 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;We sought to evaluate the safety and efficacy of a serum containing plant adaptogens (MYS) in subjects with mild-to-moderate persistent centrofacial erythema.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A multicenter, open-label trial enrolled male or female subjects 30 to 65 years of age with mild (2) to moderate (3) persistent centrofacial erythema based on a Modified Clinical Erythema grading scale (M-CEA; 0=clear to 4=severe). A subset of subjects enrolled was taking oral or topical medications for rosacea (≥6 months) with breakthrough erythema. Subjects with &gt;5 papules or pustules were excluded from participation. The investigators assessed erythema based on the M-CEA scale and global inflammatory lesions utilizing a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects assessed erythema, dryness/flaking, itching, stinging, and burning using a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects also completed self-assessment questionnaires. Digital photography and adverse events (AEs) were captured throughout the study. In addition to the study product (MYS [AM/PM]), subjects used a standardized skincare regimen that included a gentle cleanser, moisturizer, and sunscreen.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Fifty-five subjects were enrolled and 51 subjects completed the study: 38 in the Non-Medication Treatment Group (N-MTG) and 13 in the Medication Treatment Group (MTG). Significant mean reductions in the appearance of erythema of -17%, -25%, -32%, and -33% were demonstrated from baseline at Weeks 2, 4, 8, and 12 (all &lt;i&gt;P&lt;/i&gt;&lt;0.001), respectively, with each group demonstrating significant reductions over 12 weeks. Subject-assessed erythema demonstrated comparable results for both groups combined, with -22%, -30%, -34%, and -35% significant mean reductions occurring from baseline at Weeks 2, 4, 8, and 12 (all &lt;i&gt;P&lt;/i&gt;&lt;0.001). Significant mean reductions also occurred in papules/pustules at Weeks 4 (-29%), 8 (-43%), and 12 (-58%) (n=34; &lt;i&gt;P&lt;/i&gt;&lt;0.05). Subjects reported improvements in dryness/flaking, itching, stinging, and burning over the study period. After 12 weeks, subjects (94%) reported that flare-ups were not","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"32-37"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Young Adults With Acne.","authors":"Arielle Ades","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acne vulgaris is highly prevalent among young adults and is associated with psychosocial distress, yet the relationship between clinical severity and quality of life (QoL) in this population remains incompletely understood.</p><p><strong>Objective: </strong>To evaluate changes in acne severity and dermatology-related QoL among young adults aged 18 to 22 years and to explore whether improvement in clinical grading corresponds with changes in patient-reported outcomes.</p><p><strong>Methods: </strong>A pre-post observational study was conducted with 16 participants. At baseline (Week 0) and after 8 weeks of treatment, acne severity was assessed using the Global Acne Grading System (GAGS), and QoL was measured with the Dermatology Life Quality Index (DLQI). Descriptive statistics summarized demographic characteristics. Paired <i>t</i>-tests compared pre- and post-treatment scores, and correlation analysis examined the relationship between changes in GAGS and DLQI.</p><p><strong>Results: </strong>Both acne severity and dermatology-related QoL significantly improved over the 8-week treatment period; however, changes in GAGS scores were not significantly correlated with changes in DLQI scores, indicating that perceived QoL improvement did not directly mirror clinical acne improvement.</p><p><strong>Conclusion: </strong>Among young adults with acne, meaningful improvements in both clinical severity and QoL were observed following routine treatment. The lack of correlation between these changes suggests that QoL might be influenced by factors beyond visible lesion reduction, underscoring the importance of incorporating patient-reported outcomes into acne management.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3-4 Suppl 1","pages":"S24-S27"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Series: Successful Management of Refractory Plaque Psoriasis With Combined Laser Therapy and Topical Roflumilast in 2 Patients.","authors":"Timothy Kelly","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This case series describes the treatment of 2 patients with chronic plaque psoriasis refractory to conventional topical corticosteroid therapy. Both patients declined additional topical and systemic treatments and were subsequently treated monotherapy with a 1,064nm neodymium-doped yttrium aluminium garnet laser (Aerolase Neo Elite; Aerolase, Tarrytown, New York). When pruritus returned and worsened, both subjects trialed roflumilast cream 0.3% as combination therapy alongside the ongoing laser treatments. The addition of roflumilast cream greatly improved each of their symptoms, ultimately leading to resolution of pruritus and significant improvement of plaque size and texture.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3-4 Suppl 1","pages":"S20-S22"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pumping Up Dermatologic Drug Reformulation: A Review of How Proton Pump Inhibitors May Revolutionize Scleroderma Treatment.","authors":"Aaron Cheng, David G Cotter, Manisha Ahir, Mohammad A Khan, Mark D Bonnen, Yohannes T Ghebre","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Scleroderma is a rare and often debilitating connective tissue disorder of unknown etiology affecting the skin, lungs, and other visceral organs. Current medical therapies are limited and largely focused on symptoms, particularly in advanced disease. Recent preclinical studies have shown that topically reformulated proton pump inhibitors (PPIs) reduce inflammation and fibrosis, suggesting therapeutic potential in scleroderma. In this article, we explore the emerging role of PPIs as an adjuvant therapy in scleroderma. We also describe the key mechanisms of scleroderma and current therapeutic options and highlight how PPIs modulate molecular pathways central to fibrotic disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Insurance Coverage for Wound Supplies for Patients With Hidradenitis Suppurativa.","authors":"Jordan Bui, Adaora Ntukogu, Jolina T Bui, Nicole A Negbenebor","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichenoid Drug Eruption From Cetirizine Treated With Upadacitinib and Dupilumab.","authors":"Eingun James Song, Abarajithan Chandrasekaran","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cutaneous lichenoid drug eruptions (LDE) are a group of relatively uncommon adverse drug reactions characterized by widespread erythematous to violaceous scaly papules that can be difficult to differentiate from idiopathic lichen planus. Their increasing prevalence with the use of biologics, tyrosine kinase inhibitors, and immune checkpoint inhibitors has become of particular interest in dermatology. More commonly used medications, including antibiotics, antihypertensives, and nonsteroidal anti-inflammatory drugs, have also been reported to cause LDEs. While the exact pathophysiology of LDE remains to be fully elucidated, certain medications are believed to increase the antigenicity of skin proteins, thereby triggering a T-cell-mediated response via CD8+ cytotoxic T lymphocytes that target basal keratinocytes, while increased interferon γ signaling further amplifies the inflammatory process. Herein, we report a case of LDE induced by an antihistamine (cetirizine) successfully treated with both upadacitinib and dupilumab after failure of systemic corticosteroids.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"47-49"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Dupilumab on Psychological Wellbeing in Moderate-to-Severe Atopic Dermatitis Patients: A Phase IV Clinical Trial.","authors":"Chandler E Johnson, Kareem G Elhage, Riley K Spencer, Joy Q Jin, Samuel Yeroushalmi, Mitchell S Davis, Marwa Hakimi, Wilson Liao, Tina Bhutani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to prospectively evaluate the emotional impact of dupliumab treatment on patients with atopic dermatitis (AD) using a validated psychometric instrument, the Psychological General Wellbeing (PGWB) index. This index is widely used in nondermatologic conditions and assesses self-representations of intrapersonal affective and emotional states reflecting a sense of subjective wellbeing or distress.</p><p><strong>Methods: </strong>This was a Phase IV, open-label clinical trial using dupilumab for the treatment of moderate-to-severe AD. The primary endpoint was the change in PGWB score at Week 16 of dupilumab treatment compared to baseline.</p><p><strong>Results: </strong>A total of 24 participants completed the study. The change in average PGWB score after 16 weeks of treatment with dupilumab compared to baseline was not statistically significant (5.8±19.7; <i>P</i>=0.15). There was significant improvement in PGWB score at Week 52 of treatment (8.5±17.4; <i>P</i>=0.03). Mean Eczema Area and Severity Index (EASI) improvements at Weeks 16 and 52 were 60.3% and 76.8%, respectively. Regarding Investigator Global Assessment (IGA), 29.2% and 41.7% of participants achieved a score of 0 or 1 at Weeks 16 and 52, respectively.</p><p><strong>Limitations: </strong>This study did not have a control arm and was limited by small sample size.</p><p><strong>Conclusion: </strong>Treatment with dupilumab for 52 weeks was associated with improvement of psychological wellbeing, suggesting that intervention with this interleukin (IL) 4/IL-13 inhibitor is capable of restoring quality of life in these patients.</p><p><strong>Trial administration: </strong>NCT03667014.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}